Skip to main content

UBS Group AG

Position in AVXL — Anavex Life Sciences Corp.

CIK 1610520 ZURICH, V8

Position in AVXL

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$1,749,764
+$114,323 QoQ
Shares Held
569,956
+24.1% QoQ
Ownership
0.615%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 99% Shared 0% None 1%

Common Shares in AVXL Over Time

Shares Held

Position Value (USD)

Derivatives in AVXL

reported options exposure · as of Dec 31, 2023
CallValue
$0
CallShares
0
PutValue
$186,200
PutShares
20,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. AVXL ranks #218 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in AVXL

Export CSV
26 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,749,764 569,956
2025-12-31 $1,635,441 459,394
2025-09-30 $4,378,593 491,977
2025-06-30 $4,371,698 474,154
2025-03-31 $5,216,810 608,020
2024-12-31 $4,497,524 418,764
2024-09-30 $738,723 130,057
2024-06-30 $601,936 142,639
2024-03-31 $2,114,807 415,483
2023-12-31 $1,911,202 205,285
2023-12-31 $186,200 20,000
2023-09-30 $664,044 101,381
2023-06-30 $1,079,452 132,774
2023-03-31 $1,562,738 182,350
2022-12-31 $2,913,853 314,671
2022-09-30 $494,894 47,955
2022-06-30 $807,155 80,635
2022-03-31 $4,339,471 352,516
2021-12-31 $3,815,527 220,042
2021-09-30 $3,213,282 179,013
2021-06-30 $146,738 6,419
2021-03-31 $995,729 66,604
2020-12-31 $80,519 14,911
2020-09-30 $11,375 2,500
2020-06-30 $103,580 21,053
2020-03-31 $103,751 32,937